Anti-SENP1 antibody [EPR3844] - BSA and Azide free,Abcam,AB239937
ab239937 is the carrier-free version of ab108981 . Species reactivity Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Conjugation ready Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications. Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold. Compatibility This product is compatible with the Maxpar ® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar ® is a trademark of Fluidigm Canada Inc.
Host
Rabbit
Reactivity
Human
Application
ICC/IF, Flow Cyt (Intra), WB, IHC-P
Platform ID
BAB217794702
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Protease that catalyzes two essential functions in the SUMO pathway (PubMed : 10652325, PubMed : 15199155, PubMed : 15487983, PubMed : 16253240, PubMed : 16553580, PubMed : 21829689, PubMed : 21965678, PubMed : 23160374, PubMed : 24943844, PubMed : 25406032, PubMed : 29506078, PubMed : 34048572, PubMed : 37257451). The first is the hydrolysis of an alpha-linked peptide bond at the C-terminal end of the small ubiquitin-like modifier (SUMO) propeptides, SUMO1, SUMO2 and SUMO3 leading to the mature form of the proteins (PubMed : 15487983). The second is the deconjugation of SUMO1, SUMO2 and SUMO3 from targeted proteins, by cleaving an epsilon-linked peptide bond between the C-terminal glycine of the mature SUMO and the lysine epsilon-amino group of the target protein (PubMed : 15199155, PubMed : 16253240, PubMed : 21829689, PubMed : 21965678, PubMed : 23160374, PubMed : 24943844, PubMed : 25406032, PubMed : 29506078, PubMed : 34048572, PubMed : 37257451). Deconjugates SUMO1 from HIPK2 (PubMed : 16253240). Deconjugates SUMO1 from HDAC1 and BHLHE40/DEC1, which decreases its transcriptional repression activity (PubMed : 15199155, PubMed : 21829689). Deconjugates SUMO1 from CLOCK, which decreases its transcriptional activation activity (PubMed : 23160374). Deconjugates SUMO2 from MTA1 (PubMed : 21965678). Inhibits N(6)-methyladenosine (m6A) RNA methylation by mediating SUMO1 deconjugation from METTL3 and ALKBH5 : METTL3 inhibits the m6A RNA methyltransferase activity, while ALKBH5 desumoylation promotes m6A demethylation (PubMed : 29506078, PubMed : 34048572, PubMed : 37257451). Desumoylates CCAR2 which decreases its interaction with SIRT1 (PubMed : 25406032). Deconjugates SUMO1 from GPS2 (PubMed : 24943844). See full target information SENP1
Category Paths
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
Please provide the required information below so that we can quickly source your products.